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Abstract The caipain-binding domain 2 of the kininogens, the 
major plasma inhibitors of cysteine proteinases, was expressed in 
Escherichia coli. Expression of soluble protein was optimal at 
15°C and was augmented by growing the bacteria in sorbitol and 
betaine. The recombinant domain showed high affinity (Ki 0.3-1 
nM) for cathepsin L and papain, and a somewhat lower affinity 
(Ki~ 15 riM) for caipain. The binding to cathepsin H was substan- 
tially weaker, and no inhibition of actinidin and cathepsin B was 
detected. The affinity for catbepsin L was comparable to that 
reported for the domain isolated from plasma L-kininogen, 
whereas the affinities for papain and calpain were about tenfold 
lower. The latter difference may be due to the recombinant do- 
main being nonglycosylated. 
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this domain in E. coil The isolated domain was highly active, 
but had slightly lower affinities for some proteinases than those 
reported for the domain obtained by cleavage of L-kininogen. 
This difference may be due to the recombinant domain lacking 
oligosaccharide side chains. 
2. Materials and methods 
2.1. Proteinases 
Papain (EC 3.4.22.2), actinidin (EC 3.4.22.14) and the inactive pa- 
pain, derivative, S-(methylthio)papain, were obtained as described ear- 
lier [12-14]. Recombinant rat cathepsin B (EC 3.4.22.1), expressed in 
yeast [15], was a gift from Dr. John S. Mort, Shriners Hospital, Mon- 
treal, Canada. Cathepsin H (EC 3.4.22.16) and cathepsin L (EC 
3.4.22.15), purified from bovine and sheep liver, respectively [16,17], 
were donated by Dr. Robert W. Mason, Alfred I. duPont Institute, 
Wilmington, DE, USA. m-Calpain (EC 3.4.22.17), isolated from rabbit 
lung [18], was a gift from Dr. Jan-Olof Karlsson, University of G6te- 
borg, Sweden. 
I. Introduction 
The low-molecular-weight (L-) and high-molecular-weight 
(H-) kininogens are the major plasma inhibitors of cysteine 
proteinases [14]. In addition, both kininogens erve as precur- 
sors of kinins, and kininogen also participates in the contact 
phase of blood clotting [5-7]. The regions of the two kininogens 
that constitute the heavy chain after excision of the kinin seg- 
ment are identical and contain three domains homologous to 
low-molecular-weight tissue inhibitors of cysteine proteinases, 
cystatins [1,8]. However, the N-terminal domain, domain 1, 
lacks the residues important for proteinase binding in cystatins 
[9,10] and thus has no detectable inhibitory activity [8]. Both 
domains 2 and 3 inhibit papain-like cysteine proteinases, but 
domain 2 is unique in that it also inactivates calpain [8]. The 
two inhibitory domains have been isolated by proteolytic leav- 
age of plasma L-kininogen [8]. Kininogen domain 3 has also 
been expressed in E. coli, but no expression of domain 2 was 
obtained in the system used [11]. 
To enable characterization of structure-function relation- 
ships in kininogen domain 2, in particular the background for 
calpain inhibition, we have developed an expression system for 
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2.2. Construction of expression vector 
cDNA was synthesized from human liver total RNA [19] with oligo- 
d(T)~6 as primer (GeneAmp RNA PCR kit; Perkin-Elmer Cetus). A 
segment of the kininogen cDNA from nucleotides 427 to 852, contain- 
ing the sequence coding for domain 2[1], was amplified by PCR (Gene- 
Amp). The product had the expected sequence [1,20], except for a T--) C 
substitution atposition 578, leading to a Met~Thr replacement. The 
T of the published sequence was restored by site-directed mutagenesis 
(Altered Sites Mutagenesis System; Promega). A further PCR amplifi- 
cation of this cDNA fragment created aHindlII cleavage site by G--* C 
and G~T substitutions at nucleotides 451 and 453, respectively, and 
a stop codon by a G ~ T substitution at nucleotide 837, following which 
a Sall cleavage site was introduced. The PCR product was ligated into 
the expression vector (pFLAG-1; International Biotechnologies) and 
the correct sequence of the construct verified. 
2.3. Expression and purification 
E. coli, strain UT5600, transformed with the construct were grown 
at 37°C in LB medium [21], containing 0.4% (v/v) glycerol, 50/lg/ml 
ampicillin, 1M sorbitol and 2.5 mM betaine [22], to an absorbance at
600 nm of 0.5-1. Expression was induced by adding isopropyl fl-o- 
thiogalacto-pyranoside to 0.5 raM, and the bacteria were grown at 
15°C for another 14-16 h. The cells were sonicated on ice in the pres- 
ence of 1 mM EDTA and 1.5 mM of the serine proteinase inhibitor, 
4-(2-aminoethyl)-benzenesulfonyl fluoride (Pentapharm). The lysate 
was applied to a 5-ml HiTrap N-hydroxysuccinimide-activated column 
(Pharmacia Biotech), containing ~6 mg S-(carboxymethyl)papain/ml 
gel, and the bound protein was eluted at pH 11.0. The fusion protein 
was digested for 24 h at 37°C with enterokinase (Biozyme) at an 
amount of 2/lg/mg protein in 0.05 M Tris-HC1, 0.1 M NaCI, 2 mM 
EDTA, 10% (v/v) glycerol, pH 8.0. Domain 2 was isolated by gel 
chromatography ona Superdex 16/60 column (Pharmacia Biotech). 
2.4. Protein analyses 
SDS-PAGE was done on 16.5% (w/v) gels with the Tricine buffer 
system [23]. N-terminal sequences were determined as described by 
Bj6rk et al. [24]. Molecular mass was analyzed in a Kratos Kompact 
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MALDI III instrument with ~-cyano-4-hydroxycinnamic acid as ma- 
trix. Fluorescence emission spectra were measured as reported previ- 
ously [12,25]. 
2.5. Proteinase binding 
Titrations of active papain or S-(methylthio)papain w th domain 2 
for determination f apparent binding stoichiometries were monitored 
by fluorescence [12,13]. Binding stoichiometries were also determined 
by titrating 20 nM papain with increasing concentrations of inhibitor 
and assaying residual activity with the substrate, carbobenzoxy-L-phen- 
ylalanyl-L-arginine p-nitroanilide (200 pM; Bachem), in the presence of
0.5 mM dithiothreitol at pH 7.4. 
Inhibition constants and association rate constants for the interac- 
tions of domain 2 with cysteine proteinases were measured at 25°C 
[8,15,26]. 
2.6. Protein concentrations 
Concentrations of domain 2 were determined by absorbtion meas- 
urements at 280 nm with the use of a calculated molar absorption 
coefficient [27] of 12,400 M -~.cm -1 and a relative molecular mass of 
14,500 [ l ] .  
3. Results and discussion 
The expression vector was constructed to express residues 
136 to 263 of the kininogen sequence [1,20], although with 
Val-136 replaced by Leu to allow in-frame cloning into the 
vector. The recombinant domain 2 is thus slightly longer than 
that isolated by cleavage of L-kininogen, which comprised res- 
idues 141 to 262 [8]. The N-terminus of the domain was fused 
to a FLAG sequence [28], containing an enterokinase cleavage 
site, followed N-terminally by the Omp A signal sequence. The 
latter sequence was designed to transport the fusion protein to 
the periplasmic space, with concomittant cleavage of this se- 
quence. 
Expression of soluble kininogen domain 2 increased at lower 
temperatures, 15°C being optimal. The amounts were also in- 
creased by growing the bacteria in sorbitol and betaine, condi- 
tions reported to augment expression of soluble forms of other 
recombinant proteins in E. coli [22]. Lysis of whole cells by 
sonication gave the highest yield of the domain. N-terminal 
analyses showed that the signal peptide had been cleaved from 
the protein isolated in this manner. Purification by affinity 
chromatography on immobilized papain was found to give a 
higher yield than affinity chromatography on a matrix-linked 





Fig. 1. SDS-PAGE of kininogen domain 2 under educing conditions. 
Lane 1, standards with the molecular masses in KDa indicated. Lane 
2, bacterial lysate. Lane 3, eluate from matrix-linked papain. Lane 4, 
eluate from matrix-linked papain, digested with enterokinase. Lane 5, 
kininogen domain 2 after final purification by gel chromatography. 
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Fig. 2. Fluorescence-emission difference spectra between complexes of
recombinant human kininogen domain 2 (--) or cystatin C (---) with 
papain and the free proteins. The spectra were calculated from sepa- 
rately measured corrected emission spectra [25]. The concentration f 
papain was 1 pM and that of active kininogen domain 2 or cystatin C
1.2/IM. 
antibody against the FLAG sequence. The latter sequence was 
removed from the fusion protein by cleavage with enterokinase 
(Fig. 1). About 0.25 mg of purified domain 2 was obtained per 
liter of bacterial culture. 
The isolated omain 2 showed only one band in SDS-PAGE 
(Fig. 1). It had the expected N-terminal sequence [1,20] and a 
molecular mass, as determined by mass spectroscopy, of 14,521 
Da, in good agreement with the calculated mass of 14,537 Da. 
Titrations of active papain or S-(methylthio)papain with the 
isolated domain gave apparent inhibitor to enzyme binding 
stoichiometries of 1.4-1.7, indicating that the preparations con- 
tained 60-70% inhibitorily active protein. In all further analy- 
ses, calculations were based on concentrations of active inhibi- 
tor. 
The binding of domain 2 to papain was accompanied by 
fluorescence hanges (Fig. 2) highly similar to those observed 
for the binding of human cystatin C to the enzyme [25]. This 
finding indicates that the kininogen domain interacts with 
papain in a similar manner as the homologous inhibitor, 
cystatin C. 
Kininogen domain 2 showed the highest affinity for papain 
and cathepsin L of the six cysteine proteinases investigated 
(Table 1) and a somewhat lower affinity for calpain. The bind- 
ing to cathepsin H was substantially weaker, and no inhibition 
of actinidin and cathepsin B was detected. The affinity of the 
recombinant domain 2 for cathepsin L was comparable tothat 
reported previously for the domain isolated by proteolytic 
cleavage of plasma L-kininogen, whereas the affinities of the 
recombinant domain for papain and calpain were about enfold 
lower [8]. This discrepancy may be partly due to differences in 
the methodology and enzyme preparations u ed. The fact that 
the recombinant domain is not glycosylated may also have 
affected the binding to certain target proteinases. Association 
rate constants were measured only for the high-affinity 
enzymes, papain and cathepsin L, revealing rapid binding 
(Table 1). 
Comparison of the data in this work with the inhibitory 
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Table 1 
Inhibition constants (K0 and association rate constants (ka~s) for the 
binding of recombinant kininogen domain 2 to target proteinases at
25°C 
Proteinase K i (nM) 10-6.kass (M J-s -~) 
Papain 1.0 + 0.1 (n = 5) 2.9 + 0.1 (n = 13) 
Actinidin -> 1000 N.D. 
Cathepsin B -> 1000 N.D. 
Cathepsin H 110 + 17 (n = 5) N.D. 
Cathepsin L 0.3 + 0.03 (n = 13) 3.1 + 0.3 (n = 6) 
Calpain 17 + 2 (n = 5) N.D. 
The values are given with their standard errors and with the number 
of measurements in parentheses. The buffers and substrates u ed in the 
analyses were: for papain and actinidin 0.05 M Tris-HC1, 0.1 M NaCI, 
100gM EDTA, 0.5 mM DTT, 3% (v/v) acetonitrile, pH 7.4, and 20gM 
Z-Phe-Arg-AMC; for cathepsin B 0.05 M MES-NaOH, 0.1 M NaC1, 
100/gM EDTA, 0.5 mM DTT, 0.1% (w/v)poly(ethylene glycol), pH 6.0, 
and 20gM Z-Arg-Arg-AMC; for cathepsin H 0.1 M sodium phosphate, 
1 mM EDTA, 1 mM DTT, pH 6.0, and 10 uM H-Arg-AMC; for 
cathepsin L 0.1 M sodium acetate, 1mM EDTA, 1 mM DTT, 0.005% 
(w/v) Brij 35, pH 5.5, and 5 gM Z-Phe-Arg-AMC; for calpain 0.05 M 
Tris-HCl, 0.1 M NaC1, 2 mM DTT, 5 mM CaC12, 0.1% (w/v) Triton 
X-100, pH 7.4, and 1 mM Suc-Leu-Tyr-AMC. The K m values used for 
correction of the apparent K, and k,s~values for substrate competition 
have been reported elsewhere [16,17,32,33]. N D., not determined. 
properties reported previously for recombinant kininogen do- 
main 3 and for domain 3 isolated from plasma L-kininogen 
[8,11] indicates that kininogen inhibition of the physiological 
papain-like target enzymes, cathepsin B and L, is predomi- 
nantly effected by domain 3. In particular, cathepsin B is inhib- 
ited only by the latter domain, although with moderate affinity. 
The inhibition of cathepsin H by domain 2 presumably is too 
weak to be of appreciable physiological importance; like 
cathepsins B and L, this enzyme may be inhibited more strongly 
by domain 3, but such data are lacking. Although domain 2 
may contribute to kininogen inhibition of cathepsin L, the 
predominant role of this domain in kininogen function instead 
appears to be to inhibit calpain [8,29-31]. 
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